Daiichi Industrial Pharmaceuticals’ fiscal year 2026 financial results show sales of \u00a582.8 billion (up 13.1% YoY), net profit of \u00a56.1 billion (up 138.6%), reaching record highs. Segments such as Electronics & Information and Environment & Energy expanded significantly, contributing to profit growth.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4461","jir_company_name":"Daiichi Industrial Pharmaceuticals Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4461-20260513-01.pdf","jir_short_summary":"Daiichi Industrial Pharmaceuticals' fiscal year 2026 financial results show sales of \u00a582.8 billion (up 13.1% YoY), net profit of \u00a56.1 billion (up 138.6%), reaching record highs. Segments such as Electronics & Information and Environment & Energy expanded significantly, contributing to profit growth.","jir_summary":"### Performance Overview\nDaiichi Industrial Pharmaceuticals' fiscal year 2026 financial results recorded a new high with net sales of \u00a582.886 billion (up 13.1% YoY), operating income of \u00a510.17 billion (up 88.9%), and net income of \u00a56.169 billion (up 138.6%). Segment-wise, Electronics & Information and Environment & Energy saw significant growth, successfully expanding sales of high-value-added products and improving profit margins. Assets such as fixed assets and investment securities also increased, indicating a solid financial position.\n\n### Future Outlook and Impact on Shareholders\nThe company is in the second year of its medium-term management plan 'SMART 2030', targeting sales of \u00a584 billion and net profit of \u00a56.7 billion. While there are risks of increased costs due to rising crude oil and naphtha prices and geopolitical tensions in the Middle East, efforts are underway to diversify procurement sources and appropriately reflect pricing adjustments in sales. The planned annual dividend is \u00a5150, aiming to achieve stable profit returns and growth investments.","jir_financial_highlights":"Net Sales: \u00a582.886 billion (Up 13.1% YoY)\nNet Income Attributable to Owners of Parent: \u00a56.169 billion (Up 138.6% YoY)\nOperating Income: \u00a510.17 billion (Up 88.9% YoY)","jir_category":"","jir_hashtags":"#DaiichiIndustrialPharmaceuticals, #IRFinancialResults, #JapaneseStocks","jir_key_figures":"Net Sales: \u00a582.886 billion (up 13.1% YoY)\nNet Income Attributable to Owners of Parent: \u00a56.169 billion (up 138.6%)\nDividend: \u00a590 (increase)","jir_meta_title":"\u3010Daiichi Industrial Pharmaceuticals\u30112026 Financial Results\uff5cRecord High Sales of \u00a582.8 billion","jir_meta_description":"Daiichi Industrial Pharmaceuticals' fiscal year 2026 financial results show sales of \u00a582.8 billion (up 13.1% YoY), net income of \u00a56.1 billion (up 138.6%), reaching record highs. Future outlook and dividends are also explained.","jir_og_title":"\u3010Daiichi Industrial Pharmaceuticals\u30112026 Financial Results\uff5cRecord High Sales of \u00a582.8 billion","jir_og_description":"Daiichi Industrial Pharmaceuticals' 2026 financial results record sales of \u00a582.8 billion, with significant profit increases. A detailed outlook and dividend forecast are provided.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16712,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-49036","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n